pre-IPO PHARMA

COMPANY OVERVIEW

CinRx brings a new approach to biopharmaceutical development, based on its team’s successful track record in the industry and a groundbreaking model for advancing product candidates designed to fill high-value gaps in pharma portfolios. The Company’s pipeline features assets across diverse therapeutic areas, ranging from large markets to orphan indications.


LOCATION

  • Cincinnati, OH, USA
  • None, , Israel

  • THERAPEUTIC AREAS

  • Cardiovascular Disease
  • Dermatology
  • Gastrointestinal Disease

  • WEBSITE

    https://www.cinrx.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Apr 27, 2023

    CinRx Pharma Announces First Participant Dosed in CinDome’s Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis


    Oct 18, 2022

    CinRx Pharma Announces Gavin Samuels, M.D., M.B.A. as Chief Business Officer


    Sep 28, 2022

    CinRx Pharma Announces First Study Participant Dosed in CinFina’s Phase I Multiple Ascending Dose (MAD) Study of CIN-109 for the Treatment of Obesity


    Jul 25, 2022

    vTv Therapeutics Announces Investment by CinRx Pharma


    For More Press Releases


    Google Analytics Alternative